Haisco Pharmaceutical Group Co., Ltd.
Haisco Pharmaceutical Group Co., Ltd. has 4 licensing announcements in this dataset, dated 2026-01-09 to 2026-08-26.
- Country / operating region
- China
- Ticker
- 002653.SZ
- Headquarters
- 查無
- Founded
- 查無
- Business
- Biopharmaceutical research and development
- Website
- www.haisco.com
Pipeline / products
| Asset / platform | Target | Modality | Stage at announcement | Announcement date |
|---|---|---|---|---|
| HSK39004; AN01 | PDE3; PDE4 | small molecule | phase2 | 2026-01-09 |
| HSK55718; HSK51155 | Nav1.8 | small molecule | HSK55718: Phase I; HSK51155: preclinical | 2026-04-13 |
| HSK39297; NXP100; HSK42360; NXP200 | Complement Factor B; BRAF | small molecule | 查無 | 2026-06-22 |
| Preclinical autoimmune asset | 查無 | 查無 | preclinical | 2026-08-26 |
Licensing deals
| Date | Counterparty | Asset / platform | Upfront | Near-term | Milestones | Potential total | Other disclosed terms |
|---|---|---|---|---|---|---|---|
| 2026-01-09 | AirNexis Therapeutics, Inc. | HSK39004; AN01 | USD 40m | 查無 | ≤ USD 955m | ≤ USD 1063m | Equity ≈ USD 68m |
| 2026-04-13 | AbbVie Group Holdings Ltd. | HSK55718; HSK51155 | USD 30m | USD 10m | ≤ USD 705m | 查無 | — |
| 2026-06-22 | Nuvectis Pharma, Inc. | HSK39297; NXP100; HSK42360; NXP200 | USD 20m | 查無 | 查無 | 查無 | Initial development milestones ≤ USD 20m Additional milestones ≤ USD 1400m |
| 2026-08-26 | Sentivera Therapeutics, Inc. | Preclinical autoimmune asset | USD 40m | 查無 | ≤ USD 1460m | 查無 | Equity ≈ USD 35.89m |
| Counterparty | Territory | Royalties |
|---|---|---|
| AirNexis Therapeutics, Inc. | Worldwide excluding mainland China, Hong Kong, Macau and Taiwan | Royalties; sublicensing revenue sharing. |
| AbbVie Group Holdings Ltd. | Worldwide excluding mainland China, Hong Kong and Macau | 查無 |
| Nuvectis Pharma, Inc. | NXP100: worldwide ex-Greater China, India and ten listed Southeast Asian countries; NXP200: worldwide ex-Greater China | High-single-digit to mid-teen tiered royalties; sublicensing revenue share. |
| Sentivera Therapeutics, Inc. | Worldwide excluding mainland China, Hong Kong, Macau and Taiwan | Royalties; sublicensing revenue sharing. |
Catalysts
查無
Latest monthly revenue
查無
Most advanced drug
查無
Drugnews analysis
查無